Lifecore Biomedical Announces Special Stockholder Meeting
17 janv. 2025 17h24 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
United States Oral Solid Dosage Contract Manufacturing Market Set to Reach $11.70 Billion by 2029
09 janv. 2025 11h01 HE
|
Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "United States Oral Solid Dosage Contract Manufacturing Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added...
Growth Trends in the High Potency API Contract Manufacturing Market, Forecast to 2035 - Why Pharma Giants are Turning to CMOs for High-Potency API Production
08 janv. 2025 10h14 HE
|
Research and Markets
Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "High Potency API Contract Manufacturing Market by Product, Synthesis, Application, Dosage Form, End User and Region" report has been added to ...
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
07 janv. 2025 09h00 HE
|
Lifecore Biomedical, Inc.
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE)...
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h05 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
02 janv. 2025 16h05 HE
|
Lifecore Biomedical, Inc.
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3...
Contract Pharmaceutical Dose Manufacturing Industry Research: Composition, Size, Market Share and Outlook for GLP-1 Receptor Agonist Products
23 déc. 2024 10h18 HE
|
Research and Markets
Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Contract Pharmaceutical Dose Manufacturing Industry: Composition, Size, Market Share and Outlook - 2024 Edition" report has been added to ...
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
19 déc. 2024 16h05 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
19 déc. 2024 07h00 HE
|
Lifecore Biomedical, Inc.
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and...
Global CMO/CDMO Market to Reach USD 38.87 Billion by 2032, Driven by Rising Demand for Outsourced Drug Manufacturing | Research by SNS Insider
12 déc. 2024 08h00 HE
|
SNS Insider pvt ltd
Austin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CMO/CDMO Market Size Analysis: “According to SNS Insider, the CMO/CDMO Market reached USD 23.32 billion in 2023 and is anticipated to grow up to USD 38.87...